Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults
Sets the Stage for Phase 3 Clinical Trial in 2019 Phase 2 clinical trial confirmed Phase 1/2 results, again demonstrating […]
Chiasma Previews Important Upcoming Milestones
CHIASMA OPTIMAL Phase 3 topline data expected in Q3 2019 Company anticipates submitting U.S. NDA by year-end 2019, assuming positive […]
LPL Financial Announces Fourth Quarter and Full Year 2018 Earnings Release Date and Conference Call
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Leading retail investment advisory firm and independent broker/dealer LPL Financial LLC, a […]
CASMED Reports Preliminary Net Sales for the 2018 Fourth Quarter and Full Year
Record Q4 FORE-SIGHT® cerebral oximetry sales drive 18% full-year FORE-SIGHT sales growth Introduces 2019 FORE-SIGHT sales guidance BRANFORD, Conn., Jan. […]
ZAGG Inc Acquires HALO, a Leading Direct-to-Consumer Mobile Accessories Company with an Extensive IP Portfolio, for $43 Million in Cash and Stock
SALT LAKE CITY, Jan. 03, 2019 (GLOBE NEWSWIRE) — ZAGG Inc (NASDAQ:ZAGG), a global leader and innovator in accessories and […]
Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering […]
TSX News -
Colliers International Strengthens U.S. Business With Dynamic Leader
Cody Cannon Named Executive Managing Director and Greater Los Angeles Market Leader LOS ANGELES, Jan. 03, 2019 (GLOBE NEWSWIRE) — […]
Titan Machinery Inc. to Present at the 2019 ICR Conference
WEST FARGO, N.D., Jan. 03, 2019 (GLOBE NEWSWIRE) — Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural […]
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019
Fourth-quarter 2018 revenue estimated to be approximately $9.5 million, an increase of 36% over the previous quarter Full-year 2018 revenue […]
Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease
IRVING, Texas, Jan. 03, 2019 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that […]
